Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2022

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT.

R. Swoboda
  • Fonction : Auteur
S. Giebel
  • Fonction : Auteur
T. Schroeder
  • Fonction : Auteur
N. Kröger
  • Fonction : Auteur
M. Arat
  • Fonction : Auteur
B. Savani
  • Fonction : Auteur
A. Spyridonidis
  • Fonction : Auteur
R. M. Hamladji
  • Fonction : Auteur
V. Potter
  • Fonction : Auteur
Ana Berceanu
  • Fonction : Auteur
A. Rambaldi
  • Fonction : Auteur
H. Ozdogu
  • Fonction : Auteur
J. Sanz
  • Fonction : Auteur
A. Nagler
  • Fonction : Auteur

Résumé

Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). Out of 3203 patients who met the inclusion criteria, 109 patients treated with FluTBI12 and 213 treated with FB4 were included in a final matched-pair analysis. In both groups, median patient age was 41 years, first or second complete remission (CR1/CR2) proportion was 78%/22%, allo-HCT from an unrelated donor was performed in 78% of patients. The probabilities of leukemia-free survival and overall survival at 2 years in FluTBI12 and FB4 groups were 65% vs. 60% (p = 0.64) and 70% vs. 72% (p = 0.87), respectively. The cumulative incidence of relapse was 19% vs. 29% (p = 0.11), while non-relapse mortality was 16% vs. 11%, respectively (p = 0.13). There were no statistical differences in both acute and chronic graft-versus-host disease (GVHD) incidence. The probability of GVHD-free, relapse-free survival (GRFS) was 49% for both groups. FluTBI12 and FB4 are comparable myeloablative regimens before allo-HCT in AML patients transplanted in CR1 and CR2.
Fichier non déposé

Dates et versions

hal-04520569 , version 1 (25-03-2024)

Identifiants

Citer

R. Swoboda, Myriam Labopin, S. Giebel, T. Schroeder, N. Kröger, et al.. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT.. Bone Marrow Transplantation, 2022, Bone Marrow Transplantation, 58, pp.282-287. ⟨10.1038/s41409-022-01882-5⟩. ⟨hal-04520569⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More